Endpoints News – The biopharma world is here

SUBSCRIBE

top stories

Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report

8 hours ago

Newsmakers at #EHA19: Regeneron, ArQule track progress on response rates

2 days ago

UPDATED: Bluebird shares sink as analysts puzzle out $1.8M sticker shock and an unexpected delay

2 days ago

Latest

Chi-Med cuts surufatinib PhIII short; FDA greenlights Herceptin copycat from Amgen, Allergan

2 days ago

Tariq Kassum jumps from Obsidian to Celsius helm; Quell Therapeutics taps Iain McGill as new CEO

2 days ago

Under siege, investment manager Woodford faces another investment shock

2 days ago

BeiGene touts 'encouraging' response rates as the Chinese biotech mounts challenge to BTK, PD-1 leaders

2 days ago

see latest stream

People

Turns out, Rudy Tanzi didn't see much of a story about a hidden link between Enbrel and Alzheimer's either

3 days ago

J&J gains an enthusiastic endorsement from President Donald Trump for their big new drug Spravato

3 days ago

Roche catapults Thomas Schinecker to chief of diagnostics unit

5 days ago

Startups

Adding marquee investors, BlackThorn bags $76M to back an AI-driven strategy for precision neuro medicine

3 days ago

OrbiMed-backed Prelude Therapeutics raises $60M to tackle resistance to cancer treatments

4 days ago

Sticking to hottest trends in biopharma, Oncologie gathers $80M for next leg of trans-Pacific clinical journey

6 days ago

Deals

GSK's Barron joins hands with Doudna, Weissman to deploy CRISPR tech in drug discovery

3 days ago

Merck makes a $773M bet on TGFβ, acquiring a three-year-old biotech

6 days ago

Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout

6 days ago

IPOs

Hansoh grabs $1B windfall in the latest China pharma IPO to hit the Hong Kong exchange

Last week

Weeks after raising $40M, Celgene-partnered Inhibrx lays groundwork for nearly $75M public debut

Last week

Quest for safe muscarinic receptor agonists to tackle disaster prone CNS field steers Karuna to $75M IPO

Last week

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW

Subscribe to Endpoints News

Premium storiesSee all

Biopharma BD teams are speeding into the fast lane — cash in hand — as dealmaking continues to heat up in Q1 ...

Last month

The top 50 biotechs by market cap — and what their CEOs’ compensation deals tell us about biopharma

Last month

The BCMA frenzy: Tracking the 37 drugs around the world racing to overtake bluebird bio and Celgene

Last month

Top 5 Chinese players: What does Everest's landmark deal with Immunomedics say about the flurry of in-licensing to ...

Last month

Don't missSee all

Global Blood Therapeutics poised to submit application for accelerated approval, with new pivotal data on its sickle ...

2 days ago

Gene therapies seize the top of the list of the most expensive drugs on the planet — and that trend has just begun

3 days ago

As another antibiotics biotech sinks into a crisis, warnings of a sector ‘collapse’

3 days ago

Bain’s biotech team has created a $1B-plus fund — with an eye to more Big Pharma spinouts

4 days ago

Peer review See all

Jun

7

LabCorp selects its new CEO; Pfizer names ex-Genentech vet as new head of oncology R&D

May

31

Updated: Alnylam promotes longtime exec Kevin FitzGerald to CSO; Intellia Therapeutics brings on Laura Sepp-Lorenzino

May

24

Akrevia scoops ex-Arsanis chief René Russo as CEO; Scott Gottlieb jumps back into industry; Seattle Genetics raids AstraZeneca for CCO

May

17

Biogen exec Paul McKenzie heads to CSL as COO; Pulmatrix CEO resigns

May

10

Bicycle signs on new clinical execs in pipeline drive; Howard Stern signs on as FogPharma CSO

R&D channel feed

3 days ago

Savara shares are crushed as PhIII trial flunks primary, key secondaries — but they can’t stop believing

Investors are in no mood to hear biotechs tout the success of a “key” secondary endpoint when the pivotal Phase III flunks the primary goal. Just ask Savara. The Texas biotech ...

READ MORE

FDA warns of one death linked to fecal transplants

2 days ago

Synlogic, Ginkgo expand microbial discovery pact, throwing $80M investment into the mix

4 days ago

latest in R&D

Searching for the next blockbuster to follow Darzalex, J&J finds a $150M anti-CD38 drug from partner Genmab

5 days ago

NASH contender CymaBay runs into trouble as mid-stage data disappoint

5 days ago

'We kept at it': Jeffrey Bluestone plots late-stage comeback after teplizumab shown to delay type 1 diabetes

6 days ago

Aptinyx's lead drug makes cut in small fibromyalgia trial, setting the stage for larger chronic pain study

6 days ago

La Jolla whips up some love for iron overload drug with promising data snapshot

Last week

see latest stories

Pharma channel feed

4 days ago

An incensed Catalyst Pharma sues the FDA, accusing agency of bowing to political pressure and breaking federal law

After hinting it was exploring the legality of the FDA's approval of a rival drug from family-run company Jacobus Pharmaceuticals, Catalyst Pharmaceuticals on Wednesday filed a ...

READ MORE

Plagued by delays, AstraZeneca HQ costs soar to £750M as it edges toward 2020 completion

4 days ago

Fresh analysis spotlights cardio benefit of J&J's Invokana in diabetes patients without history of CV disease

4 days ago

latest in Pharma

Silicon Valley's most anticipated slide deck just dropped. What does it mean for biopharma's digital teams?

4 days ago

Merck grows Keytruda indications with head and neck cancer approval

5 days ago

With a substantial discount to Catalyst's Firdapse, is Jacobus poised to win physician, payer support for off-label adult LEMS use?

5 days ago

In a boost to Rituxan franchise, Roche nabs quick approval for polatuzumab vedotin

6 days ago

Lilly's Trulicity CV outcomes data underwhelm amid blockbuster diabetes rivalry with Novo

6 days ago

see latest stories